Penserra Capital Management LLC Aurinia Pharmaceuticals Inc. Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$17.78 - $33.08 $52,362 - $97,420	-2,945 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $327 - $706	30 Added 1.03%	2,945 $65,000
Q2 2021 Aug 12, 2021	BUY	$10.0 - $14.52 $300 - $435	30 Added 1.04%	2,915 $37,000
Q1 2021 May 13, 2021	SELL	$12.3 - $18.73 $676 - $1,030	-55 Reduced 1.87%	2,885 $37,000
Q4 2020 Feb 12, 2021	BUY	$12.94 - $16.05 $24,068 - $29,853	1,860 Added 172.22%	2,940 $40,000
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $14,245 - $17,992	1,080 New	1,080 $15,000

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.